TABLE 4.

Crossover analysis

	Adjusted HR (95% CI)	p-value
ASV versus control (both as-randomised)	1.28 (1.01–1.63)	0.043
Crossover of ASV patients
ASV withdrawal versus control as-randomised	1.44 (1.06–1.94)	0.019
Early crossover# from ASV to control (“never tried ASV”) versus control as-randomised	1.67 (0.95–2.91)	0.073
Late crossover¶ from ASV to control (“discontinued ASV”) versus control as-randomised	1.38 (0.99–1.92)	0.056
Crossover of control patients
Crossover from control to ASV versus control as-randomised	0.74 (0.42–1.30)	0.295
Early crossover# from control to ASV versus control as-randomised	0.44 (0.11–1.83)	0.258
Late crossover¶ from control to ASV versus control as-randomised	0.83 (0.46–1.52)	0.551

ASV: adaptive servo ventilation; CI: confidence interval; HR: hazard ratio. ^#: Early crossover in the ASV group refers to patient refusal of ASV despite randomisation to the ASV group, and early crossover in the control group refers to initiation of ASV within the first 2 weeks after randomisation in a patient randomised to control. ^¶: Late crossover in the ASV group refers to withdrawal of ASV >2 weeks after randomisation in patients randomised to the ASV group, and late crossover in the control group refers to initiation of ASV >2 weeks after randomisation in patients randomised to control.